Advertisement

Topics

J&J gets quick approval for new next-gen prostate cancer drug

05:47 EST 15 Feb 2018 | pharmaphorum

The FDA has approved Johnson & Johnson’s next generation prostate cancer drug, apalutamide in an early but tough to treat form of prostate cancer that has not spread. Approval of the drug, which J&J will market under the brand name Erleada...

Original Article: J&J gets quick approval for new next-gen prostate cancer drug

NEXT ARTICLE

More From BioPortfolio on "J&J gets quick approval for new next-gen prostate cancer drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...